New Brain Implant Begins Human Trials - Neuralink Update! The recent YouTube video titled
"New Brain Implant Begins Human Trials - Neuralink Update!" provides an in-depth exploration of the advancements in Brain Computer Interface (BCI) technology, particularly focusing on Neuralink and its competition from a device called the Stentrode developed by Synchron.
Overview of Brain Computer Interfaces
The video outlines the development of BCIs, which allow direct communication between the brain and external devices, presenting enormous potential for individuals with disabilities caused by injury or illness. Since its founding in 2016, Neuralink has significantly pushed the boundaries of this technology, famously conducting experiments with animals, including a monkey that played a video game using only its thoughts.
Human Trials and FDA Approvals
Interestingly, although Neuralink has garnered much media attention, the first BCI device to receive FDA approval for human trials is not Neuralink's but Synchron's Stentrode. This device is introduced through a minimally invasive procedure that carefully navigates into the brain via blood vessels, avoiding traditional surgical methods. This approach can potentially offer superior comfort and safety compared to the more invasive procedures utilized by Neuralink, which requires a portion of the skull to be removed.
The Competitive Landscape
The video emphasizes that competition in the BCI field is beneficial, driving innovation and diversity in available products. With Synchron beginning their trials in the U.S. — and the first patient being a person with ALS who can now communicate using their thoughts — this progress serves as a catalyst for both companies. Each system has unique advantages and limitations; Synchron's Stentrode offers a lower risk method with less direct contact with the brain, while Neuralink aims to provide higher fidelity brain interface through more invasive means.
The Significance for the Future
As we look forward to the evolution of BCI technology, the ongoing human trials signify an important step in medical technology. The stakes are incredibly high, with thousands of people worldwide potentially benefiting from these advancements. Neuralink has increased expectations for its trials, with Elon Musk predicting they could begin by the end of 2024. Overall, this update on Neuralink and the BCI industry is not just a reflection of technological progress but also a gateway to discussions about ethics, safety, and the future of human-computer interaction.
What are your thoughts on the competing approaches between Neuralink and Synchron? Do you think one will significantly outperform the other? Share your insights!
